What we do

For more than 45 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Corporate 08 May 2025

Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits Press Release, Corporate 08 May 2025 Hikma announces settlement agreement for Xyrem® (sodium oxybate) U.S. class action lawsuits
S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable Press Release, Corporate 08 May 2025 S&P upgrades Hikma Pharmaceuticals PLC and its Senior Notes to ‘BBB’ on continued good business momentum; outlook stable
Hikma reiterates full year guidance following good start to the year Press Release, Corporate 24 April 2025 Hikma reiterates full year guidance following good start to the year
Hikma acquires Novugen’s FDA-approved ANDA for trametinib Press Release, Product 17 April 2025 Hikma acquires Novugen’s FDA-approved ANDA for trametinib